Authors : Anchel Sharma; Savita Verma; Dharminder Singh

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/3p6ewz4b

Scribd : https://tinyurl.com/mrhjbhu4

DOI : https://doi.org/10.38124/ijisrt/26feb970

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Depression is a complicated, long-lasting, and recurrent mental illness that has a major impact on emotional, cognitive, and physical functioning and has a huge negative impact on global health. The World Health Organization (WHO) estimates that over 280 million people worldwide suffer from depression, making it a substantial contributor to the global illness burden and a primary cause of disability. In addition to lowering quality of life, the disorder raises the risk of morbidity and mortality, especially from suicide and related illnesses including diabetes and cardiovascular disease. Depression has a complex etiology that includes genetic, neurological, psychological, and environmental factors. Additionally, there is growing evidence that oxidative stress and inflammatory cytokines have a role in the neuroprogression of depression. An integrative approach that combines medication, psychotherapy, and lifestyle changes is used to treat depression. The first-line pharmaceutical treatments are still antidepressants such selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants. Psychotherapeutic approaches including interpersonal therapy (IPT) and cognitive-behavioral therapy (CBT) have also demonstrated notable effectiveness in enhancing results. Electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine-based therapies are being used more frequently for treatment-resistant cases. The potential of probiotics, anti-inflammatory drugs, and nutraceuticals as supplemental therapies has also been emphasized by recent studies. An extensive grasp of depression, including its epidemiology, symptomatology, etiology, neurobiological underpinnings, diagnostic techniques, and treatment developments, is the goal of this review. It highlights the significance of early detection, individualized treatment, and holistic care in effectively managing depression by combining recent research.

Keywords : Pathophysiology, Depression, Pharmacotherapy, Psychotherapy, Neurobiology, Neurotransmitters, and the HPA Axis.

References :

1. Stahl SM. Stahl's Essential Psychopharmacology. 5th ed. Cambridge: Cambridge University Press; 2013.
2. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO; 2017.
3. Kroenke K, Spitzer RL, Williams JB, Lowe B. The PHQ series: Validity and utility in primary care. J Gen Intern Med. 2001;16(9):606-16.
4. Salik I, Marwaha R. Electroconvulsive Therapy. [Updated 2022 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
5. Singh R, Volner K, Marlowe D. Provider Burnout. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
6. Ormel J, Kessler RC, Schoevers R. Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Curr Opin Psychiatry. 2019;32(4):348-54.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.
8. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder (focus on depressive episodes). J Clin Psychiatry. 2008;69(12):e1-e12.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.
10. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312.
11. Kupfer DJ, et al. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012;379(9820):1045–1055.
12. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537–555.
13. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):37–46.
14. Luppino FS, et al. Overweight, obesity, and depression: a systematic review and meta-analysis. Arch Gen Psychiatry. 2010;67(3):220–229.
15. Faith MS, Butryn M, Wadden TA. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev. 2011;12(5):e438–e453.
16. Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008;10(3):329–336.
17. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005;66(10):1254–1269.
18. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord. 2003;76(1-3):255–259.
19. Sobin C, Sackeim HA. Psychomotor symptoms of depression. Am J Psychiatry. 1997;154(1):4–17.
20. Buyukdura JS, McClintock SM, Croarkin PE. Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):395–409.
21. Marangell LB, et al. Fatigue as a symptom of depression: clinical and research implications. J Clin Psychiatry. 2003;64 Suppl 14:93–97.
22. Gold PW, et al. Hypothalamic–pituitary–adrenal axis activity in depression. Ann N Y Acad Sci. 1986;487:218–231.
23. Pulcu E, Zahn R, Elliott R. The role of self-blaming moral emotions in major depression. Front Psychol. 2013;4:310.
24. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312.
25. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552–1562.
26. Kendler KS, et al. The genetic epidemiology of major depression: twin study findings. Arch Gen Psychiatry. 2006;63(11):1136–1144.
27. Wray NR, et al. Genome-wide association analyses identify 44 risk variants for major depression. Nat Genet. 2018;50(5):668–681.
28. Schildkraut JJ. The catecholamine hypothesis of affective disorders. Am J Psychiatry. 1965;122(5):509–522.
29. Sanacora G, et al. Emerging insights into the neurobiology of depression: focus on the glutamate system. Mol Psychiatry. 2012;17(2):122–140.
30. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23(5):477–501.
31. Drevets WC, et al. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res. 2008;167:413–431.
32. Beck AT. Cognitive therapy and the emotional disorders. New York: International Universities Press; 1976.
33. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York: Guilford Press; 1979.
34. Seligman MEP. Learned helplessness. Annu Rev Med. 1972;23:407–412.
35. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders. Biol Psychiatry. 2001;49(12):1023–1039.
36. Lorant V, et al. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157(2):98–112.
37. Kawachi I, Berkman LF. Social ties and mental health. J Urban Health. 2001;78(3):458–467.
38. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res. 2002;53(4):859–863.
39. Moussavi S, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851–858.
40. Patten SB, Barbui C. Drug-induced depression: incidence, mechanisms and management. CNS Drugs. 2004;18(1):35–60.
41. Bloch M, et al. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2003;44(3):234–246.
42. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. Arch Gen Psychiatry. 2006;63(10):1113–1120.
43. Skodol AE, et al. Personality disorders and depression: comorbidity and implications for treatment. J Psychiatr Pract. 2002;8(5):287–293.
44. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–914.
45. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: APA; 2013.
46. World Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: WHO; 2021.
47. Rapkin, A. J., & Lewis, E. I. Treatment of premenstrual dysphoric disorder. Women’s Health. 2013;9(6):537–556.
48. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109-2113.
49. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312.
50. Wray NR, et al. Genome-wide association analyses identify risk variants for major depression. Nat Genet. 2018;50(5):668–681.
51. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders. Biol Psychiatry. 2001;49(12):1023–1039.
52. Lorant V, et al. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157(2):98–112.
53. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55–68.
54. Sanacora G, et al. Emerging insights into the neurobiology of depression: focus on the glutamate system. Mol Psychiatry. 2012;17(2):122–140.
55. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31(9):464–468.
56. Dowlati Y, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457.
57. Drevets WC, et al. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res. 2008;167:413–431.
58. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68–72.
59. Moussavi S, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851–858.
60. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–914.
61. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: APA; 2013.
62. World Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: WHO; 2021.
63. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry (11th ed.). Philadelphia: Wolters Kluwer; 2015.
64. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
65. Zimmerman M, Martinez JH. Screening for depression with the PHQ-9: A diagnostic meta-analysis. J Gen Intern Med. 2013;28(10):1326–1332.
66. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
67. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
68. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II (BDI-II). San Antonio, TX: Psychological Corp; 1996.
69. American Psychiatric Association. DSM-5. Washington DC: APA; 2013.
70. Katzung BG. Basic and Clinical Pharmacology. 15th ed. McGraw-Hill; 2021.
71. El-Den S, et al. Pharmacists’ roles in mental healthcare: past, present and future. Res Social Adm Pharm. 2019;15(3):247-254.
72. FIP. Mental health care: A handbook for pharmacists. International Pharmaceutical Federation, 2022.
73. Rubio-Valera A, et al. New roles for pharmacists in community mental health: a review. BMC Health Serv Res. 2012;12:407.
74. Mey A, et al. Engaging pharmacists in screening for depression: a review. Int J Pharm Pract. 2013;21(3):155-163.
75. Capoccia KL, et al. Integrating pharmacy-based screening for depression. J Am Pharm Assoc. 2004;44(5):556-563.
76. Al-Saffar N, et al. Counselling and education by pharmacists improves adherence in depression. Patient Educ Couns. 2005;59(2):159-165.
77. Chong WW, et al. Patient understanding of antidepressants and its effect on adherence. Int J Clin Pharm. 2011;33(3):437-444.
78. Krska J, et al. Pharmacist-led medication review in mental health. Psychiatr Serv. 2013;64(1):57-63.
79. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
80. Gisev N, et al. Medication reconciliation by pharmacists. Res Social Adm Pharm. 2010;6(2):115-122.
81. Readdean KC, et al. Impact of pharmacist interventions on adherence to antidepressants: systematic review. J Am Pharm Assoc. 2018;58(4S):S48-S56.
82. Finley PR, et al. Clinical and economic outcomes of pharmacist interventions in depression. Am J Health Syst Pharm. 2003;60(14):1417-1423.
83. Fava M. Adverse effects of antidepressant treatment. J Clin Psychiatry. 2000;61 Suppl 2:3-8.
84. Tint A, Haddad PM. Tapering and discontinuation of antidepressants. CNS Drugs. 2019;33(10):901-911.
85. Salik I, Marwaha R. Electroconvulsive Therapy. [Updated 2022 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
86. Singh R, Volner K, Marlowe D. Provider Burnout. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
87. Ormel J, Kessler RC, Schoevers R. Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Curr Opin Psychiatry. 2019;32(4):348-354.
88. Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther. 2019;199:58-90.
89. Namkung H, Lee BJ, Sawa A. Causal Inference on Pathophysiological Mediators in Psychiatry. Cold Spring Harb Symp Quant Biol. 2018;83:17-23.
90. Mangla K, Hoffman MC, Trumpff C, O'Grady S, Monk C. Maternal self-harm deaths: an unrecognized and preventable outcome. Am J Obstet Gynecol. 2019;221(4):295-303.
91. Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145-180.
92. Tanner J, Zeffiro T, Wyss D, Perron N, Rufer M, Mueller-Pfeiffer C. Psychiatric Symptom Profiles Predict Functional Impairment. Front Psychiatry. 2019;10:37.
93. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546.
94. Knappe S, Einsle F, Rummel-Kluge C, Heinz I, Wieder G, Venz J, et al. [Simple guideline-oriented supportive tools in primary care: Effects on adherence to the S3/NV guideline unipolar depression]. Z Psychosom Med Psychother. 2018;64(3):298-311.
95. Saracino RM, Nelson CJ. Identification and treatment of depressive disorders in older adults with cancer. J Geriatr Oncol. 2019;10(5):680-684.
96. Hengartner MP, Passalacqua S, Andreae A, Heinsius T, Hepp U, Rössler W, et al. Antidepressant Use During Acute Inpatient Care Is Associated With an Increased Risk of Psychiatric Rehospitalisation Over a 12-Month Follow-Up After Discharge. Front Psychiatry. 2019;10:79.
97. Rootes-Murdy K, Carlucci M, Tibbs M, Wachtel LE, Sherman MF, Zandi PP, et al. Non-suicidal self-injury and electroconvulsive therapy: Outcomes in adolescent and young adult populations. J Affect Disord. 2019;250:94-98.
98. World Health Organization. Depression. 2021.
99. Global Health Data Exchange. GBD Results Tool. 2019.